APTARGROUP, INC.

NYSE: ATR·Crystal Lake, Illinois·

Price
$143.17
Base IV
$75.18

Valuation snapshot

Above bull case

At $143.17, the price is above even our bull case of $126.94.

Values per share, from an .

No growth
…
Loading earnings power
Base case
$75.18
53% of the price · range $27.24–$126.94
Price vs base case
90% above
$143.17 against $75.18
Base casevalued by DCF
Price vs base
Priceclose 11‑16

Whisker on the base case runs bear $27.24 to bull $126.94. Values per share.

Price against each value

Bear case
$27.24
Price 426% above
No growth
…
—
Base case
$75.18
Price 90% above
Researched bygpt-6.1-sol
Valuation Nov 11, 2026 · Price as of Nov 16, 2026How we got here

What does Aptargroup do?

AptarGroup designs and manufactures dispensing pumps, aerosol valves, and primary packaging components to help pharmaceutical and consumer goods companies deliver and protect products safely.

It brought in $4B of sales in the 12 months to Sep 2026.

Led by Gael Touya, President and Chief Executive Officer since 2026. Form 8-K, September 1, 2026

Industry
Consumer discretionary
Based in
Crystal Lake, Illinois
Trades on
NYSE as ATR

Here is where each dollar a customer pays ends up. Out of every $1 of sales in the 12 months to Sep 2026, about 7¢ was left as profit after every cost, interest and tax. The biggest cost is running the business, 88¢ of every dollar.

  • Running the business88¢
  • Interest and other costs3¢
  • Tax2¢
  • Left as profit7¢
Totals of the four quarters to Sep 2026, from the company's own filings. The split by product is from the latest fiscal year.

Who pays Aptargroup, and for what?

AptarGroup designs and manufactures dosing, dispensing, and protective packaging systems such as spray pumps, closures, aerosol valves, and injectable drug components. The company earns revenue by selling these proprietary packaging technologies and drug delivery solutions to consumer and healthcare brand owners globally.

AptarGroup sells directly to approximately 5,000 businesses across pharmaceutical, beauty, personal care, home care, and food and beverage markets.

  • Pharma

    46%

    Dispensing systems, drug delivery devices, injectable primary packaging, active materials, and digital health tools for prescription and consumer healthcare markets.

  • Beauty

    35%

    Dispensing pumps, airless systems, and aerosol spray valves sold to fragrance, skincare, color cosmetics, personal care, and home care brands.

  • Closures

    19%

    Dispensing caps, flow-control closures, tethered caps, and food service trays for food, beverage, personal care, and household applications.

Share of the latest fiscal year's sales, as the company reports it.

Where its work physically happens, beyond headquarters:

  • Aptar Granville injectables plant — Granville, France. Granville is Aptar Pharma's main site for injectable elastomer components such as PremiumCoat, and a second plant there came out of the roughly $180M injectables expansion, so it underpins growth in the company's highest-margin segment.
  • Aptar Pharma Congers site — Congers, United States. Congers is Aptar's US plant for injectable elastomer components and Unidose nasal spray systems, and a 2024 expansion added 28,500 sq. ft. of cleanroom space plus PremiumCoat production for North American pharma customers.
  • Le Vaudreuil / Val-de-Reuil pharma campus and R&D center — Val-de-Reuil, France. This existing Aptar manufacturing campus now also holds a new 3,000 m² R&D center with about 170 staff that opened in 2025, which supports Aptar's drug-delivery development pipeline and the high-margin Pharma segment.
  • Suzhou Intelligent Production and R&D Base — Suzhou, China. This 60,000 m² base brings eight older workshops into one site and is one of Aptar's largest investments in Asia, serving as its advanced manufacturing hub for Asia-Pacific across all segments.
  • Aptar Mumbai (Taloja) facility — Taloja, India. This 3.5-acre plant opened in December 2023 and expanded in 2026 to add local production of pharma inhalation technologies, which positions Aptar for growth in India and South-East Asia.
See them on the globe

AptarGroup, Inc. 2025 Form 10-K

How is the business doing?

Sales grew from $2.9B in 2020 to $3.8B in 2025, about 5% a year.

Running the business leaves about 12¢ of each sales dollar as operating profit, about the same as 12¢ in 2020.

After paying for its upkeep and new investment, it had $294.7M of cash to spare in the 12 months to Sep 2026.

Sales$3.8B
20152025
Operating margin13%
20152025
Free cash flow$299.6M
20152025
Each bar is one fiscal year (2015–2025), summed from four published quarters; the latest is highlighted.

What does management say it's aiming for?

The company exists to innovate and deliver dosing, dispensing, and packaging solutions that enhance everyday life and safeguard products.

“We innovate and transform ideas into solutions that improve everyday life.”

Aptar Purpose and Vision

Who is responsible for the plan?

Roles checked November 9, 2026.

What management says it is working on now:

  • Focus on Organic Growth in High-Growth Regions

    Leverage cross-segment capabilities, existing production capacity, and shared technologies to pursue organic growth, especially in emerging, fast-growing regions.

    AptarGroup, Inc. 2025 Form 10-K
  • Core Functional Excellence

    Execute across three core pillars of operational and commercial excellence: innovate, produce, and sell.

    AptarGroup, Inc. 2025 Form 10-K
  • Cost Management and Scalable Infrastructure

    Control administrative and fixed costs by expanding Global Business Service Centers to boost operating leverage and improve return on invested capital.

    AptarGroup, Inc. 2025 Form 10-K
  • Disciplined Acquisitions and Partnerships

    Pursue selective acquisitions and commercial partnerships to expand technology platforms, geographic reach, and product portfolios with financial discipline.

    AptarGroup, Inc. 2025 Form 10-K
  • Investing in Talent and Leadership

    Recruit, retain, and develop global employees to maintain the technical and leadership capabilities required to execute strategic goals.

    AptarGroup, Inc. 2025 Form 10-K
Adjusted Diluted EPS, Q4 2026
$1.39 to $1.47
AptarGroup Q3 2026 Earnings Release
Effective Tax Rate, Q4 2026
17.5% to 19.5%
AptarGroup Q3 2026 Earnings Conference Call
Adjusted EBITDA Margin, Long-term
21% to 23%
AptarGroup Investor Presentation
Core Sales Growth, Long-term annual
4% to 7%
AptarGroup Investor Presentation
Return on Invested Capital (ROIC), Long-term
12% to 14%
AptarGroup Investor Presentation
Dividend Payout Ratio, Long-term annual
30% to 40%
AptarGroup Investor Presentation
Goals in management's own numbers. A target is a promise, not a result.

What's changing right now?

Growth is slowing. In Q3 2026 it sold 6% more than a year earlier. The year before, quarters averaged 9%.

Its operating margin is about where it was a year ago, 13¢ per sales dollar.

Since Oct 2026 the share price has risen 10%, from $130.64 to $143.17.

Bull $126.94Base $75.18Bear $27.24Oct 30Nov 16 · $143.17
Daily closing prices we have recorded, set against our bear-to-bull range. Our price records start October 30, 2026.

Recently

Coming up

  • After Q4 2026

    Normalization of Emergency Medicine Destocking

    Customer inventory drawdowns for emergency medicine dispensing formats like naloxone are anticipated to conclude, helping segment volumes recover.

    AptarGroup Q3 2026 Earnings Call
  • 2026-2027

    Commercialization of Pulmotree Pulmonary Platform

    Advancing technology integration and new client formulation wins following the acquisition of Pulmotree to expand next-generation inhaled drug delivery lines.

    Aptar Pharma News Release
  • 2026-2027

    Stevanato Group Pre-Filled Syringe Partnership Rollout

    Execution of the joint solution with Stevanato Group to offer pre-tested, integrated elastomeric components and glass syringe systems for sensitive biologics.

    Aptar Commercial Announcements
  • February 2027

    Full-Year 2026 Financial Results and 2027 Guidance

    Release of audited full-year 2026 financial performance, initial 2027 annual guidance, and updates on capital allocation plans.

    Aptar Investor Relations Financial Calendar

Our own estimate moved too: the base case went from $86.26 to $75.18 a share between our last two valuations. The biggest reason: Capital expenditure / sales, first nine months moved from an unreported prior value to 6.3%, as reported in Aptar Q3 2026 Form 10-Q, current-year figures.

What could go wrong?

No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.

  1. Tariffs, Trade Disputes, and Geopolitical Tensions

    Import tariffs and retaliatory trade countermeasures can inflate raw material and component costs, disrupt global shipping, and prompt customer order reductions.

    From the company's own filingsWould hit how much of each sale it keepsAptarGroup, Inc. 2025 Form 10-K

  2. Raw Material Price Volatility and Cost Pass-Through Limits

    Rapid price inflation in resins, rubber, metal, and energy may compress profitability if the company cannot promptly pass cost increases through to customers.

    From the company's own filingsWould hit how much of each sale it keepsAptarGroup, Inc. 2025 Form 10-K

  3. High Fixed Costs and Capacity Underutilization

    Because production relies heavily on proprietary manufacturing plants, demand downturns leave unabsorbed capacity costs that directly reduce operating margins.

    From the company's own filingsWould hit how much of each sale it keepsAptarGroup, Inc. 2025 Form 10-K

  4. Single-Source Suppliers and Plant Disruptions

    Reliance on single-source suppliers for certain specialized pharma resins and rubber components creates vulnerabilities to operational halts and delivery delays.

    From the company's own filingsWould hit how fast sales growAptarGroup, Inc. 2025 Form 10-K

  5. Stringent Environmental and Packaging Regulations

    Evolving global laws mandating recycled plastics, tethered closures, or bans on substances like PFAS force product redesigns and higher operational compliance costs.

    From the company's own filingsWould hit how much it has to reinvestAptarGroup, Inc. 2025 Form 10-K

  6. Dependence on Pharmaceutical Client Approvals

    Developing customized drug dispensing devices takes years of investment; failures in clinical trials, regulatory rejection, or commercial flops prevent cost recovery.

    From the company's own filingsWould hit how fast sales growAptarGroup, Inc. 2025 Form 10-K

  7. Nine-month Pharma core growth was zero.

    From our researchWould hit how fast sales growAptar Q3 2026 Form 10-Q

  8. Q2 Beauty profitability weakened from unfavorable mix and volumes.

    From our researchWould hit how much of each sale it keepsAptar Q2 2026 results

Is it a good business?

From 2015 to 2025 it earned between 8% and 16% on the capital invested in it, a median of 10%. Its cost of capital in the latest valuation is 7.6%; returns were above it in every one of the 10 years.

From 2015 to 2025 it earned between 12% and 18% on its shareholders' equity, a median of 15%.

Over 10 years its operating margin ranged from 11¢ to 14¢ per sales dollar, a median of 13¢. Gross margin ran from 29¢ to 31¢.

derived computed from the filingsassumption cost of capital from the latest valuation
Return on invested capital10%
20152025

Cost of capital 7.6%

Return on equity15%
20152025
Return on invested capital is operating profit after tax (at the median effective rate, 26%) over debt plus equity less cash at each fiscal year end. Return on equity is net income over equity. Both are computed from published quarters.

The number of shares grew 5% from 2015 to 2020, so each share owns a smaller slice of the business.

It owes $1.2B more than it holds in cash, about 2.5 years of operating profit.

What might it be worth?

The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .

Today a share costs $143.17. Our put its value between $27.24 and $126.94, with $75.18 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .

Bear case, $27.24

Recent sales gains fade while the weaker profitability seen this year persists, leaving Aptar growing slowly and spending heavily to keep its factories competitive.

Base case, $75.18

Aptar keeps growing at a steady pace while recovering some of the profitability lost recently as medicine orders normalize and factory performance improves.

Bull case, $126.94

Recent sales gains strengthen as medicine orders rebound and factory problems ease, allowing Aptar to earn more from each sale and turn more profit into cash.

Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.

Why the gap?

The price expects far more than we do.Price above value: 90%

For Aptargroup to be worth today's $143.17, sales would need to grow about 17.7% a year. We assume 4.6%. Over the last 5 years, sales grew 4.8% a year.

−5%0%+5%+10%+15%+20%We assume 4.6%Past 5 yrs 4.8%Price needs 17.7%

Or, if sales grow 4.6% as we assume, the price works with a profit margin of 25.1% (we assume 14.5%).

Keep in mind: investors are likely paying for things this model leaves out, such as new businesses or many more years of fast growth.

Do you think sales can grow 17.7% a year?

Try your own numbers

We're moderately sure of this range: it scores 57 out of 100 on our checks. The weakest point is terminal-value dependency.

Test the assumptions

Our base value of $75.18 rests on three assumptions. Change any of them to see how the value per share responds.

  • Revenue growth, 5-year average4.6%
  • Operating margin14.5%
  • Long-term growth rate2.5%

This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.

Base estimate

$75.18 -47.5%

Build